Repository logo
 
Publication

Sensor based sleep patterns and reported sleep quality in breast cancer patients undergoing neoadjuvant chemotherapy

2025-07-11Research article Open access
Simple item page
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorMalveiro, Carla
dc.contributor.authorBoavida, Sofia
dc.contributor.authorCargaleiro, Catarina
dc.contributor.authorBernardino, Ana V.
dc.contributor.authorCorreia, Inês R.
dc.contributor.authorReis, Cátia
dc.contributor.authorMatos, Leonor
dc.contributor.authorSardinha, Luis B.
dc.contributor.authorCardoso, Maria João
dc.contributor.authorSaint-Maurice, Pedro F.
dc.date.accessioned2025-09-02T14:26:17Z
dc.date.available2025-09-02T14:26:17Z
dc.date.issued2025-07-11
dc.description.abstractBreast cancer is the most diagnosed cancer in women worldwide and its treatment often leads to the onset of sleep disturbances. While much research has focused on chemotherapy’s impact on overall sleep quality through subjective measures, less attention has been given to its effects on specific sleep metrics such as duration, timing, continuity, and naps. This preliminary study addresses this gap by assessing sleep duration, timing, and regularity, using the Emfit QS device over 100 consecutive days in 24 breast cancer patients undergoing neoadjuvant chemotherapy. Additionally, we incorporated the Pittsburgh Sleep Quality Index (PSQI) to measure reported sleep quality. Our results suggest that chemotherapy may influence the duration for time spent in bed (ptrend=0.02) measured by the Emfit QS. Duration in bed decreased over the first seven weeks (e.g., 9.3 h/day at week 1 vs. 8.5 h/day at week 8), and increased thereafter to similar amounts as those recorded in week 1 (9.0 h/day at week 15). Sleep timing and regularity, also measured by the Emfit QS, remained unchanged. Overall sleep quality, as measured by the PSQI, did not change over time. However, our analysis of the individual components of the PSQI revealed that sleep disturbances increased as treatment progressed from week 1 to week 8 (1.3 ± 0.6 to 1.7 ± 0.6; p=0.01), concurrently with an increase in insomnia symptoms. Approximately, 33%, 63%, and 73% reported having insomnia symptoms at week 1, 8, and 15. These findings highlight critical periods during treatment when patients are vulnerable to disrupted sleep. Future research should focus on interventions to mitigate sleep disturbances, improving patient wellbeing and overall quality of life.eng
dc.identifier.citationMalveiro, C., Boavida, S., Cargaleiro, C., & Bernardino, A. V. et al. (2025). Sensor based sleep patterns and reported sleep quality in breast cancer patients undergoing neoadjuvant chemotherapy. Scientific Reports, 15(1), Article 25075. https://doi.org/10.1038/s41598-025-99208-0
dc.identifier.doi10.1038/s41598-025-99208-0
dc.identifier.eid105010527059
dc.identifier.issn2045-2322
dc.identifier.other1c6c0a80-3dae-4fde-adfe-1e4461ca2a2f
dc.identifier.pmcPMC12254343
dc.identifier.pmid40646183
dc.identifier.urihttp://hdl.handle.net/10400.14/54619
dc.identifier.wos001527596200031
dc.language.isoeng
dc.peerreviewedyes
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectBreast cancer
dc.subjectInsomnia
dc.subjectNeoadjuvant chemotherapy
dc.subjectQuality of life
dc.subjectSleep patterns
dc.titleSensor based sleep patterns and reported sleep quality in breast cancer patients undergoing neoadjuvant chemotherapyeng
dc.typeresearch article
dspace.entity.typePublication
oaire.citation.issue1
oaire.citation.titleScientific Reports
oaire.citation.volume15
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
124818630.pdf
Size:
1.58 MB
Format:
Adobe Portable Document Format
Download

Collections

CRC-W - Contribuições em Revistas Científicas / Contribution to Journals